Neumora Therapeutics IPO Presentation Deck
Offering summary
Issuer (Exchange / Ticker):
Base offering size:
Option to purchase additional shares:
Price range:
Use of proceeds:
Bookrunners:
Stabilization agent:
Expected pricing date:
Lock-up:
Neumora Therapeutics, Inc. (Nasdaq / NMRA)
14,710,000 shares (100% primary)
2,206,500 shares (15% of base deal, 100% primary)
$16.00-$18.00 per share
Neumora Therapeutics anticipates to use the net proceeds of this offering, together with its existing cash,
cash equivalents and marketable securities, as follows:
approximately $395 million to fund the clinical and preclinical development of our current programs;
approximately $30 million to fund research and development activities for additional programs; and
the remainder for working capital and other general corporate purposes.
J.P. Morgan, BofA Securities, Stifel, Guggenheim Securities, RBC Capital Markets, William Blair
●
●
●
J.P. Morgan
As early as Thursday, Septem 14th, 2023
180 days for the Company, directors, officers, affiliates and substantially all security holders
Confidential
3View entire presentation